PDS Biotechnology (PDSB) Stock Price, News & Analysis

Company Overview

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Key Stats

• Today's Range: $1.36 to $1.45
• 50-Day Range: $0.94 to $1.42
• 52-Week Range: $0.85 to $4.42
• Volume: 528,755 shs
• Average Volume: 458,555 shs
• Market Capitalization: $64.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

PDS Biotechnology Stock Analysis - MarketRank™

PDS Biotechnology scored higher than 30% of companies evaluated by MarketBeat, and ranked 1595th out of 1,850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

PDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

PDS Biotechnology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.20) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PDS Biotechnology is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PDS Biotechnology is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PDS Biotechnology has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.77% of the float of PDS Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

PDS Biotechnology has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in PDS Biotechnology has recently decreased by 1.00%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PDS Biotechnology does not currently pay a dividend.

Dividend Growth

PDS Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.77% of the float of PDS Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

PDS Biotechnology has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in PDS Biotechnology has recently decreased by 1.00%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.53

News Sentiment

PDS Biotechnology has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for PDSB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PDS Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.20% of the stock of PDS Biotechnology is held by insiders.

Percentage Held by Institutions

Only 26.84% of the stock of PDS Biotechnology is held by institutions.

PDSB Stock Analysis - Frequently Asked Questions

How have PDSB shares performed this year?

PDS Biotechnology's stock was trading at $1.63 at the beginning of 2025. Since then, PDSB shares have decreased by 12.9% and is now trading at $1.42.
View the best growth stocks for 2025 here.

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Co. (NASDAQ:PDSB) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04.
Read the conference call transcript.

Who are PDS Biotechnology's major shareholders?

PDS Biotechnology's top institutional investors include Armistice Capital LLC (9.68%), Blair William & Co. IL (0.56%) and Simplex Trading LLC.
View institutional ownership trends.

How do I buy shares of PDS Biotechnology?

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PDS Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PDS Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Adobe (ADBE), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 5/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PDSB
• CIK: 1472091
• Web: www.pdsbiotech.com
• Phone: (800) 208-3343
• Fax: 908-790-1212
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $13.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +533.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-42,940,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -139.57%
• Return on Assets: -67.22%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 2.84
• Quick Ratio: 2.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.84 per share
• Price / Book: 1.69

Miscellaneous

• Outstanding Shares: 45,673,000
• Free Float: 33,855,000
• Market Cap: $64.86 million
• Optionable: Optionable
• Beta: 1.40